Quantitative Determination of the PARP Inhibitor Olaparib (AZD 2281) in Rat Plasma using LC-MS/MS: Application to Pharmacokinetic Studies
Revu Baby Nalanda, Atla Srinivasa Rao, S. Kapileswar & B. Srivani · Journal of Pharmaceutical Research International · 2022
Purpose: Olaparib, a highly selective PARP inhibitor in advanced treatment of ovarian cancer. The method describes a simple, rapid, sensitive, specific LC-ESI-MS/MS assay for the simultaneous detection and accurate measurement of olaparib in rat plasma using telmisartan as an int...
Open access
Research Article
10.9734/jpri/2022/v34i39A36232